Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ABUS
ARBUTUS BIOPHARMA CORP
NASDAQ
$5.07
▼ DOWN 1.93% (-0.10)

KEY STATISTICS

Market Cap$1.00 B
52w High$5.45
52w Low$3.50
Dividend Yield—
Frequency—
P/E6.11
Volume4.77M
Shares Out.197.54M

COMPANY

LEADERSHIP

Lindsay Androski
CHIEF EXECUTIVE
Lindsay Androski

COMPENSATION 2026

Salary$437,750
Stock Awards$0
Incentive Plan Pay$216,512
All Other Comp.$0
Total$1,369,013

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 26, 2007
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
19

PRICE TARGET

Target High$8.50
Target Low$8.50
Target Median$8.50
Target Consensus$8.50

UPCOMING EARNINGS

DateNov 16, 2026
DayMonday
Rev. Est.$1.00M
NOV
16
MON

SPLIT RECORD

DATETYPERATIO
2010-11-04Reverse1:5

PRICE

$5.07 ▼ DOWN 1.93% (−$0.10)
OVERLAYS
$5.05$5.10$5.15$5.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.07

About Arbutus Biopharma Corp

http://www.arbutusbio.com ↗

Arbutus Biopharma develops innovative therapeutics for HBV, SARS-CoV-2, and coronaviruses, including RNA interference, capsid inhibitors, and immune modulators, through collaborations and clinical trials in the U.S.

INDUSTRY

Biotechnology

A PRODUCT ARBUTUS BIOPHARMA CORP IS KNOWN FOR

Imdusiran (AB-729)
Imdusiran (AB-729)

Imdusiran, Arbutus Biopharma's lead investigational RNAi therapeutic for chronic hepatitis B, aims to reduce viral proteins and antigens to restore immune response, currently in Phase 2a trials.

COMPETITORS

COMPETITOR
ARWR COMPARE
GILD COMPARE
GSK COMPARE
IONS COMPARE
VIR COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License$9.6M $0 ▼$178.74M ▲$9.6M ▼
Service Other$500K $0 ▼$800K ▲$500K ▼
NonCash Royalty$249K $259K ▲$181K ▼$180K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
126
LISTED HERE
25
RANKED BY POSITION SIZE
VTI
0.00% · 5.0M
XSU.TO
0.03% · 4.1M
XBI
0.17% · 3.9M
SCHA
0.02% · 753.5K
FDM
1.31% · 693.8K
JSML
0.72% · 524.3K
FESM
0.02% · 271.7K
GSSC
0.07% · 153.5K
XRS2.F
0.03% · 146.5K
LABU
0.12% · 142.5K
AVSC
0.02% · 131.3K
PRFZ
0.02% · 122.4K
RSSL
0.03% · 76.4K
BBC
0.73% · 73.6K
SILX
0.67% · 53.2K
GERM
1.62% · 41.5K
BIB
0.04% · 7.1K
WCEO
0.19% · 4.9K
AESL
1.17% · 4.5K
FLQS
0.05% · 4.4K
KBFR
0.11% · 2.4K
QSML
0.10% · 2.3K
VETS
0.03% · 1.9K
USUE.DE
0.00% · 681
RESM
0.02% · 184

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.02%
HOLDERS
254
TOP 12 OF 254 · RANKED BY POSITION SIZE
Morgan Stanley
26.7M sh · $128.44M
Two Seas Capital LP
19.1M sh · $91.66M
Whitefort Capital Management, LP
15.8M sh · $75.81M
Blackrock, Inc.
13.8M sh · $66.08M
Blackrock Inc.
11.6M sh · $35.7M
Vanguard Group Inc
9.2M sh · $44.46M
State Street Corp
7.9M sh · $37.77M
Rubric Capital Management LP
7.5M sh · $36.16M
Adar1 Capital Management, LLC
5.4M sh · $26.05M
Adage Capital Partners Gp, L.L.C.
5.0M sh · $22.77M
Barclays Plc
4.3M sh · $19.42M
Geode Capital Management, LLC
4.1M sh · $19.77M

RATINGS SNAPSHOT

Overall rating: A-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity4
Price To Earnings3
Price To Book2
Overall Score4

INSIDER TRADES

★
DIRECTOR
Sawhney Roger
Purchase · 78.8K shares
2026-06-08
★
DIRECTOR
Beardsley Robert A
Purchase · 78.8K shares
2026-06-08
★
OFFICER: CHIEF FINANCIAL OFFICER
Nguyen Tuan
Purchase · 188.4K shares
2026-02-02
★
OFFICER: CHIEF FINANCIAL OFFICER
Nguyen Tuan
Purchase · 73.5K shares
2026-02-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Chardan Capital BUY

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NBTX$41.23COMPARE
GHRS$27.94COMPARE
SEPN$38.91COMPARE
BCAX$23.43COMPARE
KURA$12.66COMPARE
SVRA$5.26COMPARE
SPRY$5.89COMPARE